StockData
BridgeBio Oncology Therapeutics, Inc. logo

BridgeBio Oncology Therapeutics, Inc. (BBOT) stock

BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.94−0.04 (-2.02%)

Close on Nov 17, 2026Market cap $155.54MP/E –Yield –

BridgeBio Oncology Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

No revenue figures for BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More BridgeBio Oncology Therapeutics figures

See a number that looks wrong?